| Literature DB >> 31793752 |
Carmelo J Panetta1,2, Erin M Galbraith1, Marat Yanavitski1, Patrick K Koller1, Binita Shah3, Sohah Iqbal3, Joaquin E Cigarroa4, Gregory Gordon5, Sunil V Rao6.
Abstract
OBJECTIVES: Investigation of novel vertical radiation shield (VRS) in reducing operator radiation exposure.Entities:
Keywords: Air Kerma; distance; dose equivalent; horizontal radiation absorbing pad; magnification
Mesh:
Substances:
Year: 2019 PMID: 31793752 PMCID: PMC7004044 DOI: 10.1002/ccd.28629
Source DB: PubMed Journal: Catheter Cardiovasc Interv ISSN: 1522-1946 Impact factor: 2.692
Figure 1(a) Position of mannequin, when testing both horizontal radiation absorbing pad (HRAP) and vertical radiation shield (VRS; white arrow) with human computational phantom. (b) Example of VRS placement (white arrow) with both the ceiling‐mounted shield and HRAP with left radial access during a clinical procedure [Color figure can be viewed at https://wileyonlinelibrary.com]
Figure 2(a) Comparison of radiation exposure to the mannequin and human computational phantom with four angles of the detector. Left anterior oblique (LAO); Right anterior oblique (RAO); caudal (Caud); cranial (Cran). LAO/Caud with significantly more radiation measured by μSv/min and mGy/hr, p < .005. (b) Increase in magnification significantly increases exposure measured with μSv/min and mGy/hr (p < .005). (c) Significant decline in μSv/min (p < .001) with no change in mGy/hr produced by the X‐ray tube (p = .732) when mannequin positioned 40 and 120 cm from femoral access site of phantom
Figure 3Radiation exposure using horizontal and vertical shields. HRAP = horizontal radiation absorbing pad; VRS = vertical radiation shield (Steradian). (a) CCL 1 (Toshiba) with significant decline in μSv/min with use of both HRAP (RadPad) and VRS (Steradian) compared to neither HRAP or VRS shields (baseline); and combination of both VRS and HRAP with further improvement in radiation protection (p < .005), with no change in mGy/hr from the X‐ray tube (p = .226). (b) CCL 2 (Phillips) with significant drop in μSv with use of VRS compared to HRAP (Microtek; p = .019) and further reduction with combination of both HRAP and VRS (p = .016), with no change in in mGy generated from the X‐ray tube (p = .353, p = .797). (c) Significant shielding in clinical cases from radiation shown as decline in μSv with the VRS and HRAP to HRAP alone (p = .001) with no significant change in mGy produced from the X‐ray tube (p = .297)
Demographics and procedure information
| No VRS ( | VRS ( |
| |
|---|---|---|---|
| Age (years) | 67.6 ± 11.3 | 68.7 ± 12.7 | .606 |
| Sex (%male) | 61.7 | 81.6 | .005 |
| BMI | 32 ± 8.14 | 32.8 ± 9.7 | .627 |
| Room 2 (%) | 84.4 | 79.6 | .474 |
| Sheath Ext (%) | 42.2 | 34.7 | .360 |
| Radial access (%) | 83.6 | 81.6 | .763 |
| Femoral access (%) | 26.6 | 16.3 | .205 |
| Radial/femoral (%) | 9.4 | 2 | .149 |
| Case w/8″ mag (%) | 2 | 47 | <.005 |
| RHC/case | 0.08 ± 0.35 | 0.04 ± 0.20 | .374 |
| HRAP (#) | 2.0 ± 0.15 | 2.0 ± 0.14 | .902 |
| CABG (graft/case) | 0.21 ± 0.7 | 0.59 ± 1.2 | .037 |
| FFRorIVUS/case | 0.15 ± 0.2 | 0.35 ± 0.78 | .111 |
| Large injection/case | 0.23 ± 0.44 | 0.29 ± 0.5 | .469 |
| PCI/case | 0.69 ± 0.85 | 0.53 ± 0.87 | .282 |
| Contrast (mL) | 122 ± 75 | 120 ± 72 | .857 |
| Dose Eq (μSv) | 26.2 ± 31.4 | 15.2 ± 13.4 | .001 |
| Air Kerma (mGy) | 1,199 ± 998 | 1,054 ± 743 | .297 |
| Frame count | 17.1 ± 12 | 17 ± 13 | .915 |
| Flourotime (min) | 13.9 ± 16.7 | 10 ± 8.8 | .044 |
Note: VRS = vertical radiation shield; BMI = body mass index; CCL A = Phillips Allura built 2008 and remaining % used CCL B (Phillips Allura built 2016); Sheath Ext = sheath extension (StandTall); 8″ Mag = magnification is set 8 in.; RHC/case = right heart catheterization performed per case; HRAP = horizontal radiation absorbing pad; CABG (graft/case) = coronary artery bypass grafts per case; FFR or IVUS = fractional flow reserve or intravascular ultrasound; Large Injection/case = left ventriculogram, aortic, iliac, femoral or subclavian angiogram performed per case; PCI = percutaneous coronary intervention; Dose Eq = dose equivalent.